Nektar Therapeutics
NKTR
Market Cap$139.95M
Close$
$1.46
135.5% upside
Current Fair Value
135.5% upsideUndervalued by 135.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $139.95 Million |
|---|---|
| Enterprise Value | $198.26 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.58 |
| Beta | 0.69 |
| Outstanding Shares | 209,737,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.33 |
|---|---|
| PEG | 6.92 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.13 |
| Enterprise Value to EBIT | -1.46 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.52 |
| Debt to Equity | 1.69 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Nektar Therapeutics
CEO: Howard Robin